Idenix Pharmaceuticals Inc

Type: Company
Name: Idenix Pharmaceuticals Inc
Nationality: United States
Web Address: http://www.idenix.com/
First reported Sep 22 2014 - Updated 16 hours ago - 1 reports

Surprising Silver Lining for Gilead Sciences, inc. Stock

Shares of Gilead Sciences ( NASDAQ: GILD     ) got knocked down last week after CVS Health ( NYSE: CVS     ) released data showing higher discontinuation rates for hepatitis C patients taking Sovaldi than Gilead Sciences saw in its clinical trials.Source: ... [Published Motley Fool Discussion Boards - Sep 22 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 3 reports

Akebia Therapeutics Appoints Ronald C. Renaud Jr. to its Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products ... [Published Investor's Business Daily - Sep 15 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Idenix Leads Baupost To Best Month In Five Years; Klarman Explains Bio-tech Investments

In the second quarter letter, Klarman spoke of the profits it made on investments such as Idenix Pharmaceuticals Inc ( NASDAQ:IDIX ). The biotech company helped make June Baupost’s best month in five years. Idenix was acquired by Merck & Co., Inc. ( NYSE:MRK ... [Published Value Walk - Sep 10 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte

BOSTON (TheStreet) -- An email from Roman W. about Achillion Pharmaceuticals kicks off this week's Biotech Stock Mailbag.Roman asks, "Adam, in your latest articles discussing the important biotech events for the rest of the year, I noticed you made no ... [Published The Street Latest - Sep 05 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 1 reports

TG THERAPEUTICS : Infinity Pharmaceuticals (INFI) Deal with AbbVie (ABBV) Boosts TG Therapeutics (TGTX) Stock

Stock in TG Therapeutics (TGTX) popped in Wednesday trading, seeing shares bounce 9.11%. Driving the gains appears to be the favorable deal secured by rival Infinity (INFI) with AbbVie (ABBV) . The deal, which gives AbbVie the right to market and commercialize ... [Published 4 Traders - Sep 04 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

Buying Biotech

By Jim Fink :Here's an important trend in the investment world right now: the recent buyouts of small- cap biotech companies like Idenix (NASDAQ: IDIX ) and Intermune (NASDAQ: ITMN ) . Why so many pharma deals?Related Biotechnology, Pharmaceutical and ... [Published BioPortfolio - Sep 03 2014]
First reported Sep 02 2014 - Updated Sep 02 2014 - 1 reports

Reveal Insider Trading for Facebook, Plug Power, Achillion Pharmaceuticals, Apple, Twitter, and Intel

PHOENIX , Sept. 2, 2014 /PRNewswire/ -- Today, Insiderslab.com revealed the latest insider trading research for Facebook ( NASDAQ: FB ), Plug Power ( NASDAQ: PLUG ), Achillion Pharmaceuticals ( NASDAQ: ACHN ), Apple ( NASDAQ: AAPL ), Twitter ( NYSE: TWTR ... [Published WGNT - Sep 02 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 1 reports

Globally patent battles for Sovaldi's commercialisation: end result may bring bad news for patients

September 01, 2014Drug Regulatory Authority of Pakistan's (DRAP's) recent decision to register Sovaldi came at a time when globally patent battles over the lucrative market for the treatment of Hepatitis C are escalating and the end result of these legal ... [Published Business Recorder - Sep 01 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

3 Reasons Merck & Co., Inc.'s Stock Could Fall

If you were lucky enough to time your purchase of Merck ( NYSE: MRK     ) during the heights of the Great Recession, your investment has probably seen a return of 100% or greater. Unfortunately, timing the stock market is practically impossible to do, ... [Published Motley Fool Discussion Boards - Aug 28 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 2 reports

There's still hunger for 'blockbuster' biotech deals

It's been a record year for health-care mergers and acquisitions. But the traditional targets—biotech companies—haven't been the main event, as buyers have increasingly looked for overseas acquisitions in tax inversion strategies."While health-care M&A ... [Published CNBC - Aug 25 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 3 reports

Merck Completes Tender Offer to Acquire Idenix

WHITEHOUSE STATION, N.J.--(EON: Enhanced Online News)--Merck announced the successful completion of the tender offer for all of the outstanding shares of common stock of Idenix Pharmaceuticals, Inc. at a purchase price of $24.50 per share. ... [Published EON Business - Aug 05 2014]
First reported Jun 09 2014 - Updated Jun 10 2014 - 14 reports

Merck agrees to buy Idenix Pharma for $3.8bn

Merck has entered into a definitive agreement to acquire Idenix Pharmaceuticals, a biopharmaceutical firm specializing in the discovery and development of drugs for treating human viral diseases, for about $3.85bn. ... [Published PBR - News - Jun 10 2014]

Quotes

Speaking about the company's new achievement CEO Kenneth Frasier stated, "Keytruda embodies Merck's unwavering commitment to pursue breakthrough science to help people who are facing the most challenging diseases."
"We are probably looking at 150,000 being treated this year, maybe slightly more - say 200,000 - next year" Alton said
...Roger Perlmutter's (EVP, president of Merck Research Laboratories) goal is to "advance an effective therapy for all patients, irrespective of the genotype of their HCV infection and regardless of comorbidities, and to achieve a very high rate of sustained virologic response following less than six weeks of active therapy." The key take home point here is that Gilead's combo regimen up for approval next month is either an eight-week or 12-week regimen...
Roman asks, "Adam, in your latest articles discussing the important biotech events for the rest of the year, I noticed you made no mention of Achillion Pharmaceuticals. Is this because you don't see any potential in their hepatitis C drugs?"

More Content

All (137) | News (66) | Reports (0) | Blogs (56) | Audio/Video (0) | Fact Sheets (1) | Press Releases (12)
sort by: Date | Relevance
The FDA Said It Has Granted Accelerated Approva... [Published Seeking Alpha - 3 hours ago]
Surprising Silver Lining for Gilead Sciences, i... [Published Motley Fool Discussion Boards - Sep 22 2014]
If Achillion's Hep C Nucleotide Isn't Best In C... [Published Seeking Alpha - Sep 16 2014]
Akebia Therapeutics Appoints Ronald C. Renaud J... [Published Investor's Business Daily - Sep 15 2014]
Akebia Therapeutics Appoints Ronald C. Renaud J... [Published Ask.com - Sep 15 2014]
Akebia Therapeutics Appoints Ronald C. Renaud J... [Published Business Wire Health News - Sep 15 2014]
Idenix Leads Baupost To Best Month In Five Year... [Published Value Walk - Sep 10 2014]
Riding Merck: The Conservative Aggressive Pharm... [Published Seeking Alpha - Sep 09 2014]
Why Is Achillion Pharmaceuticals Up Over 250% T... [Published Bidness Etc - Sep 08 2014]
Biotech Stock Mailbag: Achillion, Ariad Revisit... [Published The Street Latest - Sep 05 2014]
TG THERAPEUTICS : Infinity Pharmaceuticals (INF... [Published 4 Traders - Sep 04 2014]
Biotech ETFs Look to Build on Hot August Returns [Published Yahoo! Finance - Sep 03 2014]
Buying Biotech [Published BioPortfolio - Sep 03 2014]
Reveal Insider Trading for Facebook, Plug Power... [Published WGNT - Sep 02 2014]
Globally patent battles for Sovaldi's commercia... [Published Business Recorder - Sep 01 2014]
FirstWord Lists: Biotech's recovery kings [Published FirstWord Pharma - Aug 31 2014]
PhRMA organization honors Emory scientist with ... [Published Noodls - Aug 28 2014]
3 Reasons Merck & Co., Inc.'s Stock Could Fall [Published Motley Fool Discussion Boards - Aug 28 2014]
Biotech ETFs Hitting New Highs On Takeover News... [Published Benzinga.com - Aug 27 2014]
Veritiv Corp. For The Value Investor? [Published Seeking Alpha - Aug 26 2014]
'Fast Money' Recap: Next Stop, S&P 2,100? [Published TheStreet.com - Aug 26 2014]
'Fast Money' Recap: Next Stop, S&P 2,100? [Published The Street Latest - Aug 26 2014]
Gilead Wins Dispute with Rival Roche Over Right... [Published FDA News - Aug 26 2014]
Ariad Pharmaceuticals, Inc. (ARIA): Healthcare-... [Published InsiderMonkey.com - Aug 25 2014]
There's still hunger for 'blockbuster' biotech ... [Published CNBC - Aug 25 2014]
InterMune Acquisition Could Ignite These Biotec... [Published Yahoo! Finance - Aug 25 2014]
Trading range and strategy ideas in Big Pharma [Published Khaleej Times - Aug 25 2014]
Must-know: The Baupost Group’s 2Q14 positions [Published Yahoo! Finance - Aug 22 2014]
2014 has potential to exceed milestone year of ... [Published FiercePharma - Aug 22 2014]
Micron Technology, Inc. (MU), Idenix Pharmaceut... [Published InsiderMonkey.com - Aug 22 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Akebia Therapeutics Appoints Ronald C. Renaud J... [Published Business Wire Health News - Sep 15 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products ...
Merck – Preparing For The Next Move [Published Chimera Research Group - Proceed With Confidence - Aug 11 2014]
  Merck & Co. Inc. (MRK) -NYSE   Lately, Merck was under the spot light after Idenix Pharmaceuticals deal, paying $3.85 Billion more than triple Idenix’s market capitalization before the. The post Merck – Preparing For The Next Move appeared first ...
Merck Completes Tender Offer to Acquire Idenix [Published EON Business - Aug 05 2014]
WHITEHOUSE STATION, N.J.--(EON: Enhanced Online News)--Merck announced the successful completion of the tender offer for all of the outstanding shares of common stock of Idenix Pharmaceuticals, Inc. at a purchase price of $24.50 per share. ...
Merck Completes Tender Offer to Acquire Idenix [Published Business Wire Professional Services News - Aug 05 2014]
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck announced the successful completion of the tender offer for all of the outstanding shares of common stock of Idenix Pharmaceuticals, Inc. at a purchase price of $24.50 per share. ...
Merck Completes Tender Offer to Acquire Idenix [Published Business Wire Health News - Aug 05 2014]
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck announced the successful completion of the tender offer for all of the outstanding shares of common stock of Idenix Pharmaceuticals, Inc. at a purchase price of $24.50 per share. ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Idenix Pharmaceuticals Reports Second Quarter a... [Published GlobeNewswire: Advertising News - Jul 31 2014]
The Zacks Analyst Blog Highlights: AbbVie, Gile... [Published Financial Services - Jun 17 2014]
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announc... [Published Financial Services - Jun 13 2014]
SHAREHOLDER ALERT: Pomerantz LLP Investigates C... [Published Financial Services - Jun 13 2014]
Study Results, Updated Organization Structures,... [Published Financial Services - Jun 05 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.